Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal registrational trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia

Trial Profile

A pivotal registrational trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 18 Jan 2018 New trial record
    • 17 Jan 2018 According to an Amarin Corporation media release, Eddingpharm anticipates that the study will be completed within the next two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top